50 reports

It is also being evaluated for the treatment of Crohn' s disease, psoriatic arthritis, and asthma.

  • Arthritis
  • Cancer Immunotherapy
  • AbbVie Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.

Also frequently prevalent in this study were depression (##%), asthma (##. ##%), malignancies (##. ##%) and chronic obstructive pulmonary disease (##. ##%) (Dougados et al., 2013).

  • Arthritis
  • World
  • Market Size
  • Johnson & Johnson
  • Novartis AG
  • Eli Lilly / Sumitomo Dainippon Pharma (for Japan)

THE DRUG IN THIS FORM WAS MARKETED UNDER DIFFERENT BRAND NAMES INCLUDING ADRENALINE, ADRENALINE CHLORIDE AND ASTHMA NEFRIN.

  • Arthritis
  • Injectable Delivery
  • Neurological Disorder
  • Demand
  • Market Size

Rheumatoid arthritis

4546 5000 3864
  • PREVALENCE OF SELECTED CO-MORBIDITIES REPORTED IN THE INTERNATIONAL COMORA STUDY, BY REGION, 2014
  • Arthritis
  • Europe
  • Japan
  • Pfizer Inc.
  • Roche Group
  • 18.1 INTRODUCTION
  • SWITZERLAND HIP RECONSTRUCTION DEVICES MARKET, BY SURGERY TYPE,

IN SWITZERLAND, DISABILITY DUE TO OSTEOPOROSIS IS GREATER THAN THAT CAUSED BY CANCERS (WITH THE EXCEPTION OF LUNG CANCER) AND IS COMPARABLE OR GREATER THAN THE DISABILITY CAUSED BY VARIETY OF CHRONIC NONCOMMUNICABLE DISEASES, SUCH AS RHEUMATOID ARTHRITIS, ASTHMA, AND HIGH BLOOD PRESSURE-REL

  • Arthritis
  • Asia
  • Europe
  • Smith & Nephew Plc
  • Zimmer Biomet Holdings, Inc.
  • 18.1 INTRODUCTION
  • SWITZERLAND HIP RECONSTRUCTION DEVICES MARKET, BY SURGERY TYPE,

IN SWITZERLAND, DISABILITY DUE TO OSTEOPOROSIS IS GREATER THAN THAT CAUSED BY CANCERS (WITH THE EXCEPTION OF LUNG CANCER) AND IS COMPARABLE OR GREATER THAN THE DISABILITY CAUSED BY VARIETY OF CHRONIC NON-COMMUNICABLE DISEASES, SUCH AS RHEUMATOID ARTHRITIS, ASTHMA, AND HIGH BLOOD PRESSURE-RE

  • Arthritis
  • Asia
  • Europe
  • Forecast
  • Zimmer Biomet Holdings, Inc.
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H1 2017
  • PIPELINE BY PARADIGM BIOPHARMACEUTICALS LTD, H1 2017

Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular and Respiratory which include indications Osteoarthritis, Allergic Asthma, Arthralgia, Arthritis, Edema and Seasonal Allergic Rhinitis.

  • Arthritis
  • Chronic Pain
  • Clinical Trial
  • Therapy
  • Galapagos NV
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H2 2017
  • PIPELINE BY PARADIGM BIOPHARMACEUTICALS LTD, H2 2017

It is in preclinical stage for the treatment of allergic asthma and heart failure.

  • Arthritis
  • Clinical Trial
  • Musculoskeletal Disorder
  • Therapy
  • Galapagos NV
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2017
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2017

Asthma, Atopic Dermatitis, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Diabetic Nephropathy, Erectile Dysfunction, Glomerulonephritis, Hepatocellular Carcinoma, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Irritable Bowel Syndrome, Kidney Fibrosis,

  • Arthritis
  • Cardiovascular Drug
  • Hepatitis
  • Therapy
  • Can-Fite BioPharma Ltd.

It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis and other diseases.

  • Arthritis
  • Cancer
  • Pharmaceutical
  • Therapy
  • Incyte Corporation
  • CELLULAR BIOMEDICINE RAISES USD19.6 MILLION IN PRIVATE PLACEMENT OF SHARES
  • ACQUISITION

The company' s product portfolio includes clinical treatment protocols for the treatment of knee osteoarthritis, cancer, asthma and chronic obstructive pulmonary diseases.

  • Arthritis
  • Healthcare
  • Pharmaceutical
  • Therapy
  • Cellular Biomedicine Group Inc.

The primary outcome measure of the study is to assess the improvement in the severity of asthma as measured by change in the asthma control questionnaire (ACQ) score.

  • Arthritis
  • Europe
  • United States
  • World
  • Novartis AG
  • Number of Products under Development by Indications, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017

The company offers its products for the treatment of airways diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis and other diseases of the lung.

  • Arthritis
  • Europe
  • United States
  • Product Initiative
  • Pfizer Inc.

It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis and other diseases.

  • Arthritis
  • Blood Disease
  • United States
  • Product Initiative
  • Incyte Corporation
  • Number of Products under Development by Indication, H2 2017
  • Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017

It is in preclinical stage for the treatment of allergic asthma and heart failure.

  • Arthritis
  • Pharmaceutical
  • Therapy
  • Australia
  • Product Initiative
  • PROTEIN FOR OSTEOARTHRITIS AND ASTHMA - DRUG PROFILE
  • REJOIN - DRUG PROFILE
  • Arthritis
  • Cell Therapy
  • United States
  • World
  • Product Initiative
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2017
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2017 (CONTD..1), H2 2017

It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis and other diseases.

  • Arthritis
  • Therapy
  • United States
  • Product Initiative
  • Pfizer Inc.

Orbis has preclinical pipeline indications for pathologies including cancer, bronchiolitis, Eczema, atopic dermatitis, nephrotic syndrome, HIV, asthma, buninectomy, head and neck cancers, steroid responsive inner ear conditions, chest congestion, hemorrphoidectomy; as well as for post-surgi

  • Arthritis
  • Pharmaceutical
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company

As of February 2006, it was in Phase II stage of development for mild asthma.

  • Arthritis
  • Autoimmune Disease
  • Biosimilar
  • Monoclonal Antibody
  • United States
  • SMALL MOLECULE TO INHIBIT PDE4B AND TNF ALPHA FOR ASTHMA, COPD AND UVEITIS - DRUG PROFILE
  • DRUGS TO INHIBIT ALDOSE REDUCTASE FOR IMMUNOLOGY, OPHTHALMOLOGY, INFECTIOUS DISEASE, METABOLIC AND RESPIRATORY DISORDERS - DRUG PROFILE
  • Arthritis
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

Interleukin-##A (IL-##A) is a CD##+ T cell-derived cytokine that promotes inflammatory responses and is elevated in rheumatoid arthritis (RA), asthma, multiple sclerosis, psoriasis, and transplant rejection.

  • Arthritis
  • Autoimmune Disease
  • United States
  • Product Initiative
  • Novartis AG
  • INNOVIMMUNE BIOTHERAPEUTICS INC
  • INV-88 - DRUG PROFILE

Secondary endpoints include asthma exacerbation rate and the degree of asthma symptom control.

  • Arthritis
  • Cell Therapy
  • United States
  • Product Initiative
  • Anavex Life Sciences Corp.
  • R&D Progress
  • DALAZATIDE - DRUG PROFILE

AbbVie is also evaluating the potential of this biologic in Crohn' s disease, psoriatic arthritis, and asthma.

  • Arthritis
  • Autoimmune Disease
  • Monoclonal Antibody
  • United States
  • Product Initiative
  • PIPELINE BY REGENERON PHARMACEUTICALS INC, H2 2017

Regeneron is also developing various product candidates in clinical development for treating asthma, pain, cancer, atopic dermatitis and infectious diseases.

  • Arthritis
  • Chronic Pain
  • United States
  • World
  • Pfizer Inc.
  • SYNTHETIC PEPTIDES FOR ALLERGIC ASTHMA AND RHEUMATOID ARTHRITIS - DRUG PROFILE
  • RHEUMATOID ARTHRITIS - PIPELINE BY ANGES MG INC, H1 2017
  • Arthritis
  • Autoimmune Disease
  • Chronic Disease
  • Pathology
  • Pfizer Inc.
  • OSTEOARTHRITIS - PIPELINE BY ORTHOCYTE CORP
  • OSTEOARTHRITIS - PIPELINE BY ONO PHARMACEUTICAL CO LTD

The company has expertise in the areas of cardiovascular, asthma, diabetology, pediatrics, central nervous system, anti-infectives, NSAIDs, anti-TB and cephalosporins.

  • Arthritis
  • United States
  • Company
  • Product Initiative
  • Amgen Inc.
  • SYNTHETIC PEPTIDES FOR ALLERGIC ASTHMA AND RHEUMATOID ARTHRITIS - DRUG PROFILE
  • SODIUM HYPOCHLORITE - DRUG PROFILE
  • Arthritis
  • Autoimmune Disease
  • Chronic Disease
  • Pathology
  • Pfizer Inc.
  • INV-88 - DRUG PROFILE
  • R&D Progress

Secondary endpoints include asthma exacerbation rate and the degree of asthma symptom control.

  • Arthritis
  • Cell Therapy
  • United States
  • Product Initiative
  • Anavex Life Sciences Corp.

ABBVIE IS ALSO EVALUATING THE POTENTIAL OF THIS BIOLOGIC IN CROHN' S DISEASE, PSORIATIC ARTHRITIS, AND ASTHMA.

  • Arthritis
  • Autoimmune Disease
  • United States
  • Company
  • Product Initiative
  • Arthritis
  • Cardiovascular Drug
  • World
  • Product Initiative
  • Can-Fite BioPharma Ltd.